<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"><url><loc>https://insights.citeline.com/pink-sheet/pathways-and-standards/approval-standards/saudi-fda-offers-priority-review-rolling-submissions-for-novel-therapies-XVKJMYAMNRH6XNKLLODQ5ZPVBQ/</loc><lastmod>2026-04-16T22:50:39.9Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:50:39.9Z</news:publication_date><news:title><![CDATA[Saudi FDA Offers Priority Review, Rolling Submissions For Novel Therapies]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/B3O4p8kaSuVNJ8qhEEo6qU59dQA=/cloudfront-us-east-1.images.arcpublishing.com/norstella/ONRPVP4PCFHFTPKQGINKNWFAZQ.jpg</image:loc><image:caption><![CDATA[Saudi FDA wants to boost innovative drug development and strengthen local R&D]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/buying-time-how-much-is-lillys-foundayo-cnpv-worth-RFUVNCQ4ABGRVHAX6P6A3HNZME/</loc><lastmod>2026-04-16T22:50:07.74Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:50:07.74Z</news:publication_date><news:title><![CDATA[Buying Time: How Much Is Lilly’s Foundayo CNPV Worth?]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/yQhoFC5sUwcdpt9QKy3T_9Sp-KA=/cloudfront-us-east-1.images.arcpublishing.com/norstella/Z75R2CYLZBHQTA7C5TKTHUAU7M.jpg</image:loc><image:caption><![CDATA[The current rate for traditional priority review voucher sales could help quantify the value of a CNPV.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/ema-to-update-decade-old-guidance-on-als-trials-amid-ongoing-unmet-need-BTM5PDHPGJGJ3CIRIDZD4VG3LA/</loc><lastmod>2026-04-16T22:49:36.18Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:49:36.18Z</news:publication_date><news:title><![CDATA[EMA To Update Decade-Old Guidance On ALS Trials Amid Ongoing Unmet Need]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/gVl1cAIkE5n7M1ppbjNNxCal0RE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UYJTGT5VTZBTDGEV6XRM3GXKQE.jpg</image:loc><image:caption><![CDATA[ALS is a neurological disorder that affects motor neurons]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/rfk-jr-defends-makarys-us-fda-record-refutes-claims-of-chilled-biopharma-investment-TCMSTNFGKBHQ3LFNPCUXRN4EVE/</loc><lastmod>2026-04-16T22:49:22.717Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:49:22.717Z</news:publication_date><news:title><![CDATA[RFK Jr. Defends Makary’s US FDA Record, Refutes Claims Of Chilled Biopharma Investment]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/uymrCPGsX1DKFxVmt1NLoUkHCa0=/cloudfront-us-east-1.images.arcpublishing.com/norstella/XCEEFAX2VFFHPKAYFXQNH6JOSE.jpg</image:loc><image:caption><![CDATA[RFK Jr. defended FDA Commissioner Martin Makary's record during a House Ways and Means Committee hearing.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/r-and-d/optic-neuritis-drug-among-three-promising-treatments-to-secure-ema-prime-designations-2PZPBU2M4FHF5EXWK4SK3IJLIA/</loc><lastmod>2026-04-16T22:47:53.012Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:47:53.012Z</news:publication_date><news:title><![CDATA[Optic Neuritis Drug Among Three Promising Treatments To Secure EMA PRIME Designations]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/O520dUqpOqb54aoi1vANXiLAwqI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/VBFBWQDWINDRPBNCCIEW5YNTHM.jpg</image:loc><image:caption><![CDATA[Optic neuritis is a rare, sight-threatening condition ]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/pathways-and-standards/approval-standards/relief-for-low-t-us-fda-eyes-literature-based-expansion-for-testosterone-therapy-BVDYVTTEIJFEPMUAWDADPKTMII/</loc><lastmod>2026-04-16T22:47:25.074Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:47:25.074Z</news:publication_date><news:title><![CDATA[Relief For ‘Low T’? US FDA Eyes Literature-Based Expansion For Testosterone Therapy]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/qTBzN4RZ_B0-kN6ywWTaK5K5yxA=/cloudfront-us-east-1.images.arcpublishing.com/norstella/INM3X27OTBENLGAAF5HWCSI32I.jpg</image:loc><image:caption><![CDATA[Published literature supports using testosterone therapy for low libido due to idiopathic hypogonadism, the FDA said.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-principal-deputy-commissioner-moving-to-hhs-as-senior-counselor-for-public-health-C64ZB6WRTNEJ7MC7I3ZY3KNP6I/</loc><lastmod>2026-04-16T22:46:31.878Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:46:31.878Z</news:publication_date><news:title><![CDATA[US FDA’s Principal Deputy Commissioner Moving To HHS As Senior Counselor For Public Health]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/1CNBCMjyA3kN88cIzXzvIWksqNk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/S2XEQTM2D5AEZGTKAGNHLGNQNY.jpg</image:loc><image:caption><![CDATA[More HHS leadership shifts coming ahead of the mid-term elections.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/beauty/policy-and-regulation/qa-with-dsm-firmenich-on-parsol-shields-expected-impact-on-us-market-WVMHFVXYWFB6ZHCLZFNHBMFDLY/</loc><lastmod>2026-04-16T22:27:22.17Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:27:22.17Z</news:publication_date><news:title><![CDATA[Q&A With DSM-Firmenich On PARSOL Shield’s Expected Impact On US Market ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/9F7bGyotii8oszC2af9N_JmWsQE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/NTL5IBEOTJHSFI4B25I6BCS7QY.jpg</image:loc><image:caption><![CDATA[US FDA's proposed order to add DSM-Firmenich's bemotrizinol UV filter, known commercially as PARSOL Shield, to the sunscreen monograph 'meaningfully expands the sunscreen formulator’s toolbox,' says company.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/health/business/deals/eight-members-of-kenvue-executive-suite-will-move-to-similar-posts-at-kimberly-clark-TOSRW4H26RGHHGCQIZEALT2TOI/</loc><lastmod>2026-04-16T22:03:42.023Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T22:03:42.023Z</news:publication_date><news:title><![CDATA[Eight Members Of Kenvue Executive Suite Will Move To Similar Posts At Kimberly-Clark  ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/WKxDQK2SNKg1OD64d5h5yLxO0RU=/cloudfront-us-east-1.images.arcpublishing.com/norstella/DICAO642TJG4DL4WVPGYEOV4WI.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/policy-and-regulation/us-fda/industry-cold-on-cms-proposal-to-repeal-fast-track-breakthrough-pathway-for-ntap-4XHDFHMTTBAYPHJKEMADPHMBFI/</loc><lastmod>2026-04-16T21:16:59.42Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T21:16:59.42Z</news:publication_date><news:title><![CDATA[Industry Cold On CMS Proposal To Repeal Fast-Track Breakthrough Pathway For NTAP ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/EToeQWGJMbpWf1tqZVoSZrk5QdI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/RSJ4544PXRDWNH2I5WMFILCVMY.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/r-and-d/clinical-trials/lilly-to-head-to-fda-after-demonstrating-foundayos-cardiovascular-liver-safety-PRUP4NN6ZZD3HJ5D6OGPBY3LME/</loc><lastmod>2026-04-16T20:43:19.39Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T20:43:19.39Z</news:publication_date><news:title><![CDATA[Lilly To Head To FDA After Demonstrating Foundayo’s Cardiovascular, Liver Safety]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/75Jf6d-5hFHWNHGXvSJdXmyNfK4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/7PHFYFQ23FFL5J5GZC6JIBXD74.jpg</image:loc><image:caption><![CDATA[Lilly announced results from the ACHIEVE-4 trial of Foundayo in type 2 diabetes among overweight and obese adults at risk of a cardiovascular event.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/digital-technologies/ai/pharma-gains-a-seat-at-the-ai-table-as-anthropic-taps-novartiss-narasimhan-OC27XEDICFHQZJJYUXNULFE5IY/</loc><lastmod>2026-04-16T20:41:39.939Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T20:41:39.939Z</news:publication_date><news:title><![CDATA[Pharma Gains A Seat At The AI Table As Anthropic Taps Novartis’s Narasimhan]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/oh2I9hKzeSjmXwLV1C6kzLU2edo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/ZMBWL2VWVFJUVO5WLCM4VG3BCU.jpg</image:loc><image:caption><![CDATA[Novartis CEO Vas Narasimhan]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/strategy/diamyd-down-in-the-dumps-after-diabetes-drug-fail-HXQSUJWZYZACNIVEL5P74WNFS4/</loc><lastmod>2026-04-16T20:40:45.296Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T20:40:45.296Z</news:publication_date><news:title><![CDATA[Diamyd Down In The Dumps After Diabetes Drug Fail]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/vELRt6X4zD9NQZAhg97h2COCOA8=/cloudfront-us-east-1.images.arcpublishing.com/norstella/HAHBD3NIAZPYNBOF5JL6UU7J2M.jpg</image:loc><image:caption><![CDATA[US supreme court decision allows Kabi to terminate Akorn deal]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/financing/storm-raises-56m-to-take-rna-modification-inhibitor-into-phase-ii-SIJQ3UU2YZF7ZN23MREF36EKDA/</loc><lastmod>2026-04-16T20:40:12.29Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T20:40:12.29Z</news:publication_date><news:title><![CDATA[Storm Raises $56m To Take RNA Modification Inhibitor Into Phase II]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/kuS4Xotj0lsZogkP-xJVpNVQTkk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/NABMC3GGZJCGJO4B7ZVWOQED64.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/leadership/executives-on-the-move/executives-on-the-move-ailux-gets-a-new-cso-from-astrazeneca-Z4BVITZIDNE7PBBOZDCCAQMKWI/</loc><lastmod>2026-04-16T20:39:42.679Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T20:39:42.679Z</news:publication_date><news:title><![CDATA[Executives On The Move: Ailux Gets A New CSO From AstraZeneca]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/h4fVGgwOIyO4RzeYcyFoc_E91Qo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QSTAM7SGMJOYTGEBU2RZSDKLYA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/business/deals/avanos-ceo-says-aip-deal-strengthens-companys-competitive-position-FV7DODANYZCG3IVEBI5VHKF374/</loc><lastmod>2026-04-16T19:27:08.933Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T19:27:08.933Z</news:publication_date><news:title><![CDATA[Avanos CEO Says AIP Deal Strengthens Company’s Competitive Position]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/YbC2YKZyINU75xFQhqCmr0RmUKs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/XOCVJ5DTBNFBNHOF4NYFROFPOU.jpg</image:loc><image:caption><![CDATA[Upon completion of the transaction, which is expected in the second half of 2026, Avanos will become a private company and its common stock will no longer be listed on the New York Stock Exchange.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/leadership/execs-on-the-move-april-610-2026-EJJVZFRT3BDTXIGA7KGR3GHK74/</loc><lastmod>2026-04-16T17:42:52.669Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T17:42:52.669Z</news:publication_date><news:title><![CDATA[Execs On The Move: April 6–10, 2026]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/h4fVGgwOIyO4RzeYcyFoc_E91Qo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QSTAM7SGMJOYTGEBU2RZSDKLYA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/products/biosimilars/henlius-targets-one-of-oncologys-toughest-biosimilars-ZHKRQWNHXFB2PIZHMMLH5I5QRI/</loc><lastmod>2026-04-16T15:43:25.812Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T15:43:25.812Z</news:publication_date><news:title><![CDATA[Henlius Targets One Of Oncology’s Toughest Biosimilars]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/9ROkCtiOJdDAHp6gQ9RidmsJA0w=/cloudfront-us-east-1.images.arcpublishing.com/norstella/XMZZOBUSZJGYZP4OYSJNWMF43Y.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/rare-diseases/us-fdas-literature-based-leucovorin-approval-may-offer-a-rare-disease-template-Z34IYMFF35ENVJXV4N4ZT4GG6Q/</loc><lastmod>2026-04-16T15:39:05.494Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T15:39:05.494Z</news:publication_date><news:title><![CDATA[US FDA’s Literature-Based Leucovorin Approval May Offer A Rare Disease Template ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/2fI8u5cRbcjja51drwkJWDUhRyg=/cloudfront-us-east-1.images.arcpublishing.com/norstella/HVD4SJONQRBYJG54VSUTN56WZU.jpg</image:loc><image:caption><![CDATA[Tracy Beth Høeg said the leucovorin approval in cerebral folate deficiency could be a template for other rare diseases.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/products/generics/apotex-snatches-first-fda-generic-approval-for-sandozs-multivitamin-injection-KTBWWCCHDFEI3HBHRAAVN622CA/</loc><lastmod>2026-04-16T15:36:01.364Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T15:36:01.364Z</news:publication_date><news:title><![CDATA[Apotex Snatches First FDA Generic Approval For Sandoz’s Multivitamin Injection]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/73nV8qXj-lf_B0qkkgCISTEsJqo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QUKUKIXR3FDABJKZGCFDWC4GWI.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/health/business/strategy/people-on-the-move-appointments-at-haleon-clasado-ck-life-sciences-7PUKGVLDWNHRBK3SRYWARZGITY/</loc><lastmod>2026-04-16T15:35:03.467Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T15:35:03.467Z</news:publication_date><news:title><![CDATA[People On The Move: Appointments At Haleon, Clasado, CK Life Sciences]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/XRh-5oJ5WoSHVjEL4B3D8Dpf02c=/cloudfront-us-east-1.images.arcpublishing.com/norstella/DKTPK5V2NNPOVFXHWRKOPKEK4M.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/policy-regulation/us-fda-peptide-review-signals-policy-shift-but-manufacturing-regulatory-hurdles-persist-RSOAIYFYV5E4LH5XY5JUZAL2GU/</loc><lastmod>2026-04-16T13:05:48.603Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T13:05:48.603Z</news:publication_date><news:title><![CDATA[US FDA Peptide Review Signals Policy Shift, But Manufacturing, Regulatory Hurdles Persist]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/1sVJPYy7bHdNmizVFYfZx4iKofE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/SG4GWQQZJBGGXDIE3DLYV4MXMU.jpg</image:loc><image:caption><![CDATA[An FDA advisory committee will consider lifting restrictions on some peptides after the agency restricted them in 2023.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/business/deals/towa-targets-supply-resilience-with-networked-manufacturing-shift-BCQK7FVYRJG3LERP4WG5JWMSQA/</loc><lastmod>2026-04-16T12:11:13.539Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T12:11:13.539Z</news:publication_date><news:title><![CDATA[Towa Targets Supply Resilience With Networked Manufacturing Shift]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/a4ZKYafnyL8Bo3Ujt3j2z1cW4t0=/cloudfront-us-east-1.images.arcpublishing.com/norstella/NMHA52LRBFO2XJALIGTACNI2ZY.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/business/deals/sandoz-builds-new-model-for-african-drug-access-C46QLZ74GJBZ3DLUVT4MEVN4GU/</loc><lastmod>2026-04-16T10:30:23.44Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T10:30:23.44Z</news:publication_date><news:title><![CDATA[Sandoz Builds New Model For African Drug Access]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/t_9iEHCwRrP3Xq2eIY6J6nLdXBw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/AYWGEWI3FVPLZJ5S364BSXHNGA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/business/supply-chain/prolonged-us-blockade-of-iran-ports-risks-drug-shortages-wider-supply-chain-woes-SEMZ4LNEPVA63KV7XAUFT6VCJY/</loc><lastmod>2026-04-16T09:32:43.569Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T09:32:43.569Z</news:publication_date><news:title><![CDATA[Prolonged US Blockade Of Iran Ports Risks Drug Shortages, Wider Supply Chain Woes]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/_ynXHk6n6kXasqPeYEY4TEGwTDQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/6B2NLA3LNBDAPKLB4OGCGYCEJI.jpg</image:loc><image:caption><![CDATA[Pharma's Supply Chain Risks Might Widen If US Continues Iran Port Blockade]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/market-access/prolonged-iran-ports-blockade-risks-drug-shortages-wider-supply-chain-woes-OVV2Q5N5RBFARHDE44FPU6XK5A/</loc><lastmod>2026-04-16T09:26:49.432Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T09:26:49.432Z</news:publication_date><news:title><![CDATA[Prolonged Iran Ports Blockade Risks Drug Shortages, Wider Supply Chain Woes]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/t2uGrXbrImnkjA2XhokAhWNJiUY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/7PWBKJNARRBJJGPSUZRTV5LACQ.jpg</image:loc><image:caption><![CDATA[Pharma's Supply Chain Woes Could Expand If Freight Disruptions Continue]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/market-access/iran-war-indias-supply-chain-shocks-contract-stress-and-spillover-risks-JRHOJ72OW5D5HANQX2PR6FYMII/</loc><lastmod>2026-04-16T09:04:29.308Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T09:04:29.308Z</news:publication_date><news:title><![CDATA[Iran War: India’s Supply Chain Shocks, Contract Stress And Spillover Risks ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/8joRpBnp4uYSFB73KUtJETw0C28=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YVA3TROSBFCRRLECVFM6YUZ73Y.jpg</image:loc><image:caption><![CDATA[Pharma tackles supply chain shocks in India]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/in-vivo/leadership/rising-leaders/rising-leaders-helping-ai-software-enter-healthcare-systems-and-markets-6XQQYKBKIRA6VDZIJDIL2K5FDI/</loc><lastmod>2026-04-16T08:51:45.017Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T08:51:45.017Z</news:publication_date><news:title><![CDATA[Rising Leaders: Helping AI Software Enter Healthcare Systems And Markets ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/wQVUNQbB4bEzwEzR5ZhC9B1rla0=/cloudfront-us-east-1.images.arcpublishing.com/norstella/CIEYX2OT2RDKRPZOTTRLJGVS4Q.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/iran-war-indias-supply-chain-shocks-contract-stress-and-spillover-risks-M7A2H6KTIZAW5MIV2YAF3AWQIQ/</loc><lastmod>2026-04-16T08:51:42.208Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T08:51:42.208Z</news:publication_date><news:title><![CDATA[Iran War: India’s Supply Chain Shocks, Contract Stress And Spillover Risks]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/8joRpBnp4uYSFB73KUtJETw0C28=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YVA3TROSBFCRRLECVFM6YUZ73Y.jpg</image:loc><image:caption><![CDATA[Pharma tackles supply chain shocks in India]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/in-vivo/leadership/rising-leaders/rising-leaders-helping-eu-device-innovators-clear-the-green-agendas-hurdles-4E7ORM5MVNDPJP6WCK6FQZPYDI/</loc><lastmod>2026-04-16T08:47:16.673Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T08:47:16.673Z</news:publication_date><news:title><![CDATA[Rising Leaders: Helping EU Device Innovators Clear The Green Agenda’s Hurdles ]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/k1EQzVLI6KbKulZs34HLHR3rqK4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/Z4FAK2ZITNAZVAATSF3BJT2NFU.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/in-vivo/leadership/rising-leaders/rising-leaders-2026-christina-coughlins-pioneering-immuno-oncology-career-2QYSTENFXJHYTNAPVB52D4MSHU/</loc><lastmod>2026-04-16T08:43:25.268Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T08:43:25.268Z</news:publication_date><news:title><![CDATA[Rising Leaders 2026: Christina Coughlin’s Pioneering Immuno-Oncology Career]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/R-1CE_qBmxNmxFLTjvG8TlkEzfg=/cloudfront-us-east-1.images.arcpublishing.com/norstella/JK6HAGTATZNRRLNFAVIMIBPJCU.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/business/financing/dd-pharmatech-raises-154m-to-progress-mash-core-assets-XD6EZWLU2VF4XIOFEW26QTT7WU/</loc><lastmod>2026-04-16T07:50:11.039Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T07:50:11.039Z</news:publication_date><news:title><![CDATA[D&D Pharmatech Raises $154m To Progress MASH, Core Assets]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/lsrvUIVGPlUDZjtmzOhunnYky2U=/cloudfront-us-east-1.images.arcpublishing.com/norstella/BIBIH2CXVFF6TJM4J4DBUTPZ2I.jpg</image:loc><image:caption><![CDATA[Expects To Confirm Positive Phase II MASH Results By End-May]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/leadership/interviews/alphamabs-bispecific-phase-iii-win-in-breast-cancer-lays-runway-for-take-off-W62ZI5XSDVCOFKM5EC22EKFUHQ/</loc><lastmod>2026-04-16T05:16:57.456Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T05:16:57.456Z</news:publication_date><news:title><![CDATA[Alphamab’s Bispecific Phase III Win In Breast Cancer Lays Runway For Take Off]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/QByWLYYFLGqGlKoxCfQhv78uD0k=/cloudfront-us-east-1.images.arcpublishing.com/norstella/N7TOWQXANFKJXIT5B3BTKRDHBM.jpg</image:loc><image:caption><![CDATA[Alphamab Oncology's CEO talks about the firm's late-stage anti-HER2 bispecific antibody and ADC and rationales of developing the first-in-class ADCs. ]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/deals/daiichi-sankyo-tightens-oncology-focus-through-otc-divestment-to-suntory-HSPKYD2BXJDYZI2IFN2NWBCZVY/</loc><lastmod>2026-04-16T03:05:23.497Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T03:05:23.497Z</news:publication_date><news:title><![CDATA[Daiichi Sankyo Tightens Oncology Focus Through OTC Divestment To Suntory]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/vUGDuACi66Tta8Cf-mBYm_uP4Ds=/cloudfront-us-east-1.images.arcpublishing.com/norstella/EKWPP4SRXNFJ5KRD33XEBEE7MQ.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/beauty/policy-and-regulation/compliance/uk-oxybenzone-limits-take-effect-july-2026-2UFQO6TW45DTZDS323UJJFIXLU/</loc><lastmod>2026-04-16T01:32:14.075Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T01:32:14.075Z</news:publication_date><news:title><![CDATA[UK Oxybenzone Limits Take Effect July 2026]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/Qri2stWfyqu3kauOHqbsTNdR2Bc=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YUILLFMWP5ILZO7FJPFCYVUJRA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/product-reviews/post-marketing-regulation-and-studies/us-fdas-speedy-cnpv-approvals-come-with-postmarket-safety-strings-attached-YCCKXTCIQRFH5NLMATSVGEV2EI/</loc><lastmod>2026-04-16T00:27:45.799Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:27:45.799Z</news:publication_date><news:title><![CDATA[US FDA’s Speedy CNPV Approvals Come With More Postmarket Safety Strings Attached]]></news:title></news:news><image:image><image:loc>https://insights.citeline.com/resizer/3j2-PON4BBpwxnMAdEr6Fu0Qs_Y=/cloudfront-us-east-1.images.arcpublishing.com/norstella/CGKJFJEGLBBTNMJTYTGDBEZTPU.jpg</image:loc><image:caption><![CDATA[Some early CNPV approvals have come with postmarketing safety strings attached.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/companies/mingren-pharmaceutical-inc</loc><lastmod>2026-04-16T00:11:09.127Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:11:09.127Z</news:publication_date><news:title><![CDATA[Mingren Pharmaceutical Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/enlitic</loc><lastmod>2026-04-16T00:11:02.938Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:11:02.938Z</news:publication_date><news:title><![CDATA[Enlitic]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/remegenix</loc><lastmod>2026-04-16T00:10:57.148Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:57.148Z</news:publication_date><news:title><![CDATA[RemeGenix]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/6j-biotechnology</loc><lastmod>2026-04-16T00:10:44.01Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:44.01Z</news:publication_date><news:title><![CDATA[6J Biotechnology]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/mezoo-co-ltd</loc><lastmod>2026-04-16T00:10:41.858Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:41.858Z</news:publication_date><news:title><![CDATA[Mezoo Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/humanova</loc><lastmod>2026-04-16T00:10:39.77Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:39.77Z</news:publication_date><news:title><![CDATA[Humanova]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/acurion</loc><lastmod>2026-04-16T00:10:37.839Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:37.839Z</news:publication_date><news:title><![CDATA[Acurion]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/onco-innovations-au-pty-ltd</loc><lastmod>2026-04-16T00:10:35.96Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:35.96Z</news:publication_date><news:title><![CDATA[Onco-Innovations AU Pty. Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/sai-life-sciences</loc><lastmod>2026-04-16T00:10:33.914Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:33.914Z</news:publication_date><news:title><![CDATA[Sai Life Sciences]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanghai-yuansong-biotechnology-co-ltd</loc><lastmod>2026-04-16T00:10:29.776Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:29.776Z</news:publication_date><news:title><![CDATA[Shanghai Yuansong Biotechnology Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/westlake-university</loc><lastmod>2026-04-16T00:10:26.182Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:26.182Z</news:publication_date><news:title><![CDATA[Westlake University]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/vanderbilt-university-medical-center</loc><lastmod>2026-04-16T00:10:21.583Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:21.583Z</news:publication_date><news:title><![CDATA[Vanderbilt University Medical Center]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/eir-biopharma-inc</loc><lastmod>2026-04-16T00:10:17.666Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:17.666Z</news:publication_date><news:title><![CDATA[EIR Biopharma, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/benethera-biotechnology-co-ltd</loc><lastmod>2026-04-16T00:10:13.831Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:13.831Z</news:publication_date><news:title><![CDATA[Benethera Biotechnology Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/coiled-therapeutics-inc</loc><lastmod>2026-04-16T00:10:09.517Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:09.517Z</news:publication_date><news:title><![CDATA[Coiled Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/cisen-pharmaceutical-co-ltd</loc><lastmod>2026-04-16T00:10:01.451Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:10:01.451Z</news:publication_date><news:title><![CDATA[Cisen Pharmaceutical Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/arnatar-therapeutics</loc><lastmod>2026-04-16T00:09:57.471Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:57.471Z</news:publication_date><news:title><![CDATA[Arnatar Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/cerba-research-nv</loc><lastmod>2026-04-16T00:09:53.466Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:53.466Z</news:publication_date><news:title><![CDATA[Cerba Research NV]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/pop-biotechnologies</loc><lastmod>2026-04-16T00:09:49.319Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:49.319Z</news:publication_date><news:title><![CDATA[POP Biotechnologies]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/pilatus-biosciences-inc</loc><lastmod>2026-04-16T00:09:45.365Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:45.365Z</news:publication_date><news:title><![CDATA[Pilatus Biosciences Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/dermolab-pharma-ltd</loc><lastmod>2026-04-16T00:09:41.214Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:41.214Z</news:publication_date><news:title><![CDATA[Dermolab Pharma Ltd]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/syncell-inc</loc><lastmod>2026-04-16T00:09:37.093Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:37.093Z</news:publication_date><news:title><![CDATA[Syncell, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shenzhen-celconta-life-science-co-ltd</loc><lastmod>2026-04-16T00:09:33.302Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:33.302Z</news:publication_date><news:title><![CDATA[Shenzhen Celconta Life Science Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/empyrean-medical-systems</loc><lastmod>2026-04-16T00:09:29.568Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:29.568Z</news:publication_date><news:title><![CDATA[Empyrean Medical Systems]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/crossbridge-bio-inc</loc><lastmod>2026-04-16T00:09:25.138Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:25.138Z</news:publication_date><news:title><![CDATA[CrossBridge Bio, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/overt-bio-inc</loc><lastmod>2026-04-16T00:09:21.164Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:21.164Z</news:publication_date><news:title><![CDATA[OverT Bio, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/dryox-health</loc><lastmod>2026-04-16T00:09:17.064Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:17.064Z</news:publication_date><news:title><![CDATA[Dryox Health]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/primoris-therapeutics</loc><lastmod>2026-04-16T00:09:12.066Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:12.066Z</news:publication_date><news:title><![CDATA[Primoris Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/tern-therapeutics-llc</loc><lastmod>2026-04-16T00:09:06.162Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:06.162Z</news:publication_date><news:title><![CDATA[Tern Therapeutics, LLC]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/cureverse</loc><lastmod>2026-04-16T00:09:00.16Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:09:00.16Z</news:publication_date><news:title><![CDATA[Cureverse]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/innobm-pharmaceuticals-co-ltd</loc><lastmod>2026-04-16T00:08:53.903Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:53.903Z</news:publication_date><news:title><![CDATA[Suzhou Baimai Biopharmaceutical Co., Ltd]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/pinkdx-inc</loc><lastmod>2026-04-16T00:08:47.942Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:47.942Z</news:publication_date><news:title><![CDATA[PinkDx, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/roquefort-therapeutics-plc</loc><lastmod>2026-04-16T00:08:41.942Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:41.942Z</news:publication_date><news:title><![CDATA[Roquefort Therapeutics PLC]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/relive-biotechnologies-ltd</loc><lastmod>2026-04-16T00:08:36.047Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:36.047Z</news:publication_date><news:title><![CDATA[ReLive Biotechnologies Ltd]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/starmab-biologics-coltd</loc><lastmod>2026-04-16T00:08:29.899Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:29.899Z</news:publication_date><news:title><![CDATA[Starmab biologics Co,.ltd]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/remedy-plan-therapeutics</loc><lastmod>2026-04-16T00:08:23.975Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:23.975Z</news:publication_date><news:title><![CDATA[Remedy Plan Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/galactica-pharmaceuticals-inc</loc><lastmod>2026-04-16T00:08:17.653Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:17.653Z</news:publication_date><news:title><![CDATA[Galactica Pharmaceuticals, Inc.,]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/reconnect-labs-ag</loc><lastmod>2026-04-16T00:08:11.752Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:11.752Z</news:publication_date><news:title><![CDATA[Reconnect Labs AG]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/eitan-medical-ltd</loc><lastmod>2026-04-16T00:08:05.713Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:08:05.713Z</news:publication_date><news:title><![CDATA[Eitan Medical Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/renumemo-therapeutics</loc><lastmod>2026-04-16T00:07:59.684Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:59.684Z</news:publication_date><news:title><![CDATA[RenuMemo Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/sensorium-therapeutics</loc><lastmod>2026-04-16T00:07:53.658Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:53.658Z</news:publication_date><news:title><![CDATA[Sensorium Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/synerk-inc</loc><lastmod>2026-04-16T00:07:47.701Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:47.701Z</news:publication_date><news:title><![CDATA[SynerK, Inc. ]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/targed-biopharmaceuticals-bv</loc><lastmod>2026-04-16T00:07:41.497Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:41.497Z</news:publication_date><news:title><![CDATA[TargED Biopharmaceuticals B.V.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/egret-therapeutics-inc</loc><lastmod>2026-04-16T00:07:35.831Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:35.831Z</news:publication_date><news:title><![CDATA[Egret Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/gigamune</loc><lastmod>2026-04-16T00:07:29.736Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:29.736Z</news:publication_date><news:title><![CDATA[GigaMune Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/ennodc</loc><lastmod>2026-04-16T00:07:23.515Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:23.515Z</news:publication_date><news:title><![CDATA[EnnoDC]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shenzhen-rhegen-biotechnology-co-ltd</loc><lastmod>2026-04-16T00:07:17.406Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:17.406Z</news:publication_date><news:title><![CDATA[Shenzhen Rhegen Biotechnology Co., Ltd. ]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/adela</loc><lastmod>2026-04-16T00:07:11.485Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:11.485Z</news:publication_date><news:title><![CDATA[Adela]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/scribe-therapeutics-inc</loc><lastmod>2026-04-16T00:07:05.777Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:07:05.777Z</news:publication_date><news:title><![CDATA[Scribe Therapeutics, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/enveda</loc><lastmod>2026-04-16T00:06:59.211Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:59.211Z</news:publication_date><news:title><![CDATA[Enveda]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/vincerx-pharma-inc</loc><lastmod>2026-04-16T00:06:53.647Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:53.647Z</news:publication_date><news:title><![CDATA[Vincerx Pharma, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/hokkaido-university</loc><lastmod>2026-04-16T00:06:47.255Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:47.255Z</news:publication_date><news:title><![CDATA[Hokkaido University]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/tranquis-therapeutics</loc><lastmod>2026-04-16T00:06:41.192Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:41.192Z</news:publication_date><news:title><![CDATA[Tranquis Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/certa-therapeutics</loc><lastmod>2026-04-16T00:06:35.259Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:35.259Z</news:publication_date><news:title><![CDATA[Certa Therapeutics]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/anivive-lifesciences</loc><lastmod>2026-04-16T00:06:29.125Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:29.125Z</news:publication_date><news:title><![CDATA[Anivive Lifesciences]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/gaia-biomedicine-co-ltd</loc><lastmod>2026-04-16T00:06:23.338Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:23.338Z</news:publication_date><news:title><![CDATA[Gaia BioMedicine Co. Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanxi-xinbaoyuan-pharmaceutical-co-ltd</loc><lastmod>2026-04-16T00:06:11.043Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:11.043Z</news:publication_date><news:title><![CDATA[Shanxi Xinbaoyuan Pharmaceutical Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/palleon-pharmaceuticals-inc</loc><lastmod>2026-04-16T00:06:05.302Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:06:05.302Z</news:publication_date><news:title><![CDATA[Palleon Pharmaceuticals Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/travera-llc</loc><lastmod>2026-04-16T00:05:59.174Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:59.174Z</news:publication_date><news:title><![CDATA[Travera LLC]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/puracap-pharmaceutical-llc</loc><lastmod>2026-04-16T00:05:52.818Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:52.818Z</news:publication_date><news:title><![CDATA[PuraCap Pharmaceutical LLC]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/clalit-health-services</loc><lastmod>2026-04-16T00:05:46.87Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:46.87Z</news:publication_date><news:title><![CDATA[Clalit Health Services]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/futura-medical-plc</loc><lastmod>2026-04-16T00:05:41.082Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:41.082Z</news:publication_date><news:title><![CDATA[Futura Medical plc]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/pyxis-oncology</loc><lastmod>2026-04-16T00:05:35.128Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:35.128Z</news:publication_date><news:title><![CDATA[Pyxis Oncology]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/frontier-medicines-corp</loc><lastmod>2026-04-16T00:05:28.907Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:28.907Z</news:publication_date><news:title><![CDATA[Frontier Medicines Corp.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/tel-aviv-sourasky-medical-center</loc><lastmod>2026-04-16T00:05:16.737Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:16.737Z</news:publication_date><news:title><![CDATA[Tel Aviv Sourasky Medical Center]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/university-of-cincinnati</loc><lastmod>2026-04-16T00:05:10.703Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:10.703Z</news:publication_date><news:title><![CDATA[University of Cincinnati]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/vectus-biosystems-limited</loc><lastmod>2026-04-16T00:05:05.006Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:05:05.006Z</news:publication_date><news:title><![CDATA[Vectus Biosystems Limited]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/university-of-bristol</loc><lastmod>2026-04-16T00:04:58.484Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:58.484Z</news:publication_date><news:title><![CDATA[University of Bristol]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/confometrx</loc><lastmod>2026-04-16T00:04:52.652Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:52.652Z</news:publication_date><news:title><![CDATA[ConfometRx, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/aventacell-biomedical-corp</loc><lastmod>2026-04-16T00:04:46.384Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:46.384Z</news:publication_date><news:title><![CDATA[AventaCell BioMedical Corp.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/ethypharm</loc><lastmod>2026-04-16T00:04:40.265Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:40.265Z</news:publication_date><news:title><![CDATA[Ethypharm]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanghai-junshi-biosciences-co-ltd</loc><lastmod>2026-04-16T00:04:34.43Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:34.43Z</news:publication_date><news:title><![CDATA[Shanghai Junshi Biosciences Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/iterum-therapeutics-plc</loc><lastmod>2026-04-16T00:04:28.389Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:28.389Z</news:publication_date><news:title><![CDATA[Iterum Therapeutics plc]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/shanghai-raas-blood-products-co-ltd</loc><lastmod>2026-04-16T00:04:22.211Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:22.211Z</news:publication_date><news:title><![CDATA[Shanghai RAAS Blood Products Co., Ltd.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/philogen-spa</loc><lastmod>2026-04-16T00:04:16.235Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:16.235Z</news:publication_date><news:title><![CDATA[Philogen S.p.A.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/promis-neurosciences-inc</loc><lastmod>2026-04-16T00:04:07.551Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:04:07.551Z</news:publication_date><news:title><![CDATA[ProMIS Neurosciences, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/biostax-corp</loc><lastmod>2026-04-16T00:03:55.223Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:03:55.223Z</news:publication_date><news:title><![CDATA[Biostax Corp.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/spectral-medical-inc</loc><lastmod>2026-04-16T00:03:43.13Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:03:43.13Z</news:publication_date><news:title><![CDATA[Spectral Medical Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/stanford-university</loc><lastmod>2026-04-16T00:03:31.036Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:03:31.036Z</news:publication_date><news:title><![CDATA[Stanford University]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/diasorin-spa</loc><lastmod>2026-04-16T00:03:19.279Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:03:19.279Z</news:publication_date><news:title><![CDATA[DiaSorin]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/clinuvel-pharmaceuticals-limited</loc><lastmod>2026-04-16T00:03:07.103Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:03:07.103Z</news:publication_date><news:title><![CDATA[Clinuvel Pharmaceuticals Limited]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/microport-scientific-corporation</loc><lastmod>2026-04-16T00:02:55.103Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:02:55.103Z</news:publication_date><news:title><![CDATA[MicroPort Scientific Corporation]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/exicure-inc</loc><lastmod>2026-04-16T00:02:43.055Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:02:43.055Z</news:publication_date><news:title><![CDATA[Exicure, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/corin-orthopaedics-holdings-limited</loc><lastmod>2026-04-16T00:02:30.876Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:02:30.876Z</news:publication_date><news:title><![CDATA[Corin Group]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/r-biopharm-ag</loc><lastmod>2026-04-16T00:02:06.876Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:02:06.876Z</news:publication_date><news:title><![CDATA[R-Biopharm AG]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/hepion-pharmaceuticals-inc</loc><lastmod>2026-04-16T00:01:54.916Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:01:54.916Z</news:publication_date><news:title><![CDATA[Hepion Pharmaceuticals, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/cosciens-biopharma</loc><lastmod>2026-04-16T00:01:42.792Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:01:42.792Z</news:publication_date><news:title><![CDATA[COSCIENS Biopharma]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/precigen-inc</loc><lastmod>2026-04-16T00:01:30.764Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:01:30.764Z</news:publication_date><news:title><![CDATA[Precigen, Inc.]]></news:title></news:news></url><url><loc>https://insights.citeline.com/companies/provectus-biopharmaceuticals-inc</loc><lastmod>2026-04-16T00:01:19.381Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><news:news><news:publication><news:name>Insights</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-16T00:01:19.381Z</news:publication_date><news:title><![CDATA[Provectus Biopharmaceuticals, Inc.]]></news:title></news:news></url></urlset>